Liposomal amphotericin B and surgery as successful therapy for pulmonary Lichtheimia corymbifera zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazole Authors
First Online: 10 January 2013 Received: 13 September 2012 Accepted: 15 October 2012 DOI:
10.1007/s12032-012-0433-3 Cite this article as: Kleinotiene, G., Posiunas, G., Raistenskis, J. et al. Med Oncol (2013) 30: 433. doi:10.1007/s12032-012-0433-3 Abstract
Pulmonary zygomycosis, also referred to as mucormycosis, is a fungal infection of lungs caused by fungi of the order Mucorales in the class of Zygomycetes. It is usually associated with high morbidity and mortality. Here, we report the case of a 14-year-old girl with pediatric acute promyelocytic leukemia (APL) on antifungal prophylaxis with posaconazole, who developed pulmonary
Lichtheimia corymbifera (formerly Absidia corymbifera) zygomycosis. She was successfully treated by means of liposomal amphotericin B (L-AmB) and surgery. To our knowledge, this is the first published report on pediatric APL and pulmonary zygomycosis in the English language literature. At present, the patient is in complete remission of her APL and without any signs of recurrence of zygomycosis. This report suggests that efficient diagnostics, increased physician awareness, and reliance on adjunctive surgical therapy can result in a favorable outcome of pulmonary zygomycosis in immunocompromised children with hematological malignancies. Keywords Acute promyelocytic leukemia Children Lichtheimia corymbifera Invasive fungal infection Pediatric Treatment Zygomycosis References
Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1–53.
Björkholm M, Runarsson G, Celsing F, Kalin M, Petrini B, Engervall P. Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia. Scand J Infect Dis. 2001;33:316–9.
Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect. 2009;15(Suppl 5):55–9.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.
Anderson ML. Infectious causes of bovine abortion during mid- to late-gestation. Theriogenology. 2007;68:474–86.
Piancastelli C, Ghidini F, Donofrio G, et al. Isolation and characterization of a strain of Lichtheimia corymbifera (ex Absidia corymbifera) from a case of bovine abortion. Reprod Biol Endocrinol. 2009;7:138.
Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45:1351–60.
Liu ZH, Lv GX, Chen J, et al. Primary cutaneous zygomycosis due to Absidia corymbifera in a patient with cutaneous T cell lymphoma. Med Mycol. 2009;47:663–8.
Horré R, Jovanic B, Herff S, et al. Wound infection due to Absidia corymbifera and Candida albicans with fatal outcome. Med Mycol. 2004;42:373–8.
Mohammed S, Sahoo TP, Jayshree RS, et al. Sino-oral zygomycosis due to Absidia corymbifera in a patient with acute leukemia. Med Mycol. 2004;42:475–8.
Hopwood V, Hicks DA, Thomas S, Evans EGV. Primary cutaneous zygomycosis due to Absidia corymbifera in a patient with AIDS. J Med Vet Mycol. 1992;30:399–402.
Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007;45:321–46.
Torres-Narbona M, Guinea J, Martinez-Alarcon J, et al. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol. 2007;45:2051–3.
Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27:1138–47.
Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67.
Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the retrozygo study (2005–2007). Clin Infect Dis. 2012;54(Suppl 1):S35–43.
Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis. 2007;26:723–7.
Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol. 2009;31:911–9.
Giacchino M, Milano GM, Carraro F, et al. Current evidence of antifungal prophylaxis and therapy in pediatric patients. Pediatr Rep. 2011;3:e6.
O’Brien D, Lim CH, Farrell M, et al. Invasive intracerebral fungal infection in a leukaemic patient. Br J Neurosurg. 2012;26:423–5.
Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematol. 2008;119:73–82.
Bally C, Fadlallah J, Leverger G, et al. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL group. J Clin Oncol. 2012;30:1641–6.
Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950–2.
Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425–9.
Schalk E, Mohren M, Jentsch-Ullrich K, et al. Zygomycoses in patients with acute leukaemia. Ann Hematol. 2006;85:327–32.
Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004;58:612–24.
Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310–2.
Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–33.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2013